what are oral glp-1 medications GLP-1s rapidly expanding user base Comparing Ozempic, Wegovy and Other

Parallel efforts are exploring new indications, including neurodegenerative and substance use disorders, metabolic liver disease, arthritis, type 1 diabetes and inflammatory bowel disease

ATTAIN-1 trial: 12.4% average weight loss at the highest dose over 72 weeks

Side effects can have varying impacts on individuals as everyone is different

High patient out-of-pocket costs and side effects are causing a large percentage of people who start on weight loss medications to stop

Disclosure of safety information in foreign countries The GLP-1 receptor agonist used for this treatment has been approved for the indication of obesity by the FDA in the United States, the MFDS in South Korea, and the EMA in EU27 countries

Annual Review of Nutrition , 29, 2141